STROBE Statement—Checklist of items that should be included in reports of cohort studies

<table>
<thead>
<tr>
<th>Item No</th>
<th>Recommendation</th>
<th>Reported on page</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Title and abstract</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>(a) Indicate the study’s design with a commonly used term in the title or the abstract</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>(b) Provide in the abstract an informative and balanced summary of what was done and what was found</td>
<td>3</td>
</tr>
<tr>
<td><strong>Introduction</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Explain the scientific background and rationale for the investigation being reported</td>
<td>5</td>
</tr>
<tr>
<td><strong>Objectives</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>State specific objectives, including any prespecified hypotheses</td>
<td>5</td>
</tr>
<tr>
<td><strong>Methods</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Study design</strong></td>
<td>4</td>
<td>Present key elements of study design early in the paper</td>
</tr>
<tr>
<td></td>
<td></td>
<td>6 and separately referenced protocol paper</td>
</tr>
<tr>
<td><strong>Setting</strong></td>
<td>5</td>
<td>Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection</td>
</tr>
<tr>
<td></td>
<td></td>
<td>6-7</td>
</tr>
<tr>
<td><strong>Participants</strong></td>
<td>6</td>
<td>(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up</td>
</tr>
<tr>
<td></td>
<td></td>
<td>6-7</td>
</tr>
<tr>
<td></td>
<td>(b) For matched studies, give matching criteria and number of exposed and unexposed</td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Variables</strong></td>
<td>7</td>
<td>Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable</td>
</tr>
<tr>
<td></td>
<td></td>
<td>6-7</td>
</tr>
<tr>
<td><strong>Data sources/measurement</strong></td>
<td>8*</td>
<td>For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group</td>
</tr>
<tr>
<td></td>
<td></td>
<td>6-7</td>
</tr>
<tr>
<td><strong>Bias</strong></td>
<td>9</td>
<td>Describe any efforts to address potential sources of bias</td>
</tr>
<tr>
<td><strong>Study size</strong></td>
<td>10</td>
<td>Explain how the study size was arrived at</td>
</tr>
<tr>
<td><strong>Quantitative variables</strong></td>
<td>11</td>
<td>Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why</td>
</tr>
<tr>
<td><strong>Statistical methods</strong></td>
<td>12</td>
<td>(a) Describe all statistical methods, including those used to control for confounding</td>
</tr>
<tr>
<td></td>
<td>(b) Describe any methods used to examine subgroups and interactions</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td>(c) Explain how missing data were addressed</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td>(d) If applicable, explain how loss to follow-up was addressed</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td>(e) Describe any sensitivity analyses</td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Results</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Participants</strong></td>
<td>13*</td>
<td>(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility,</td>
</tr>
</tbody>
</table>
confirmed eligible, included in the study, completing follow-up, and analysed

(b) Give reasons for non-participation at each stage 8-10

(c) Consider use of a flow diagram Figure 1

<table>
<thead>
<tr>
<th>Descriptive data</th>
<th>14*</th>
<th>(a) Give characteristics of study participants (e.g., demographic, clinical, social) and information on exposures and potential confounders 8-10 and Tables 1</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>(b) Indicate number of participants with missing data for each variable of interest N/A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(c) Summarise follow-up time (e.g., average and total amount) N/A</td>
</tr>
</tbody>
</table>

| Outcome data    | 15* | Report numbers of outcome events or summary measures over time 8-10                                                                                                                              |

| Main results    | 16  | (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% confidence interval). Make clear which confounders were adjusted for and why they were included N/A |
|                 |     | (b) Report category boundaries when continuous variables were categorized Table 1                                                                                                                   |
|                 |     | (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period N/A                                                                                 |

| Other analyses  | 17  | Report other analyses done—e.g., analyses of subgroups and interactions, and sensitivity analyses N/A                                                                                             |

<table>
<thead>
<tr>
<th>Discussion</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Key results</td>
<td>18</td>
</tr>
<tr>
<td>Limitations</td>
<td>19</td>
</tr>
<tr>
<td>Interpretation</td>
<td>20</td>
</tr>
<tr>
<td>Generalisability</td>
<td>21</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Other information</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Funding</td>
<td>22</td>
</tr>
</tbody>
</table>

*Give information separately for exposed and unexposed groups.